Myriad Genetics, Inc. (MYGN Quick QuoteMYGN – Free Report) reported adjusted earnings per share (EPS) of 4 cents in the second quarter of 2022, surpassing the Zacks Consensus Estimate of an adjusted EPS of 2 cents. However, the metric plunged 66.7% from the year-ago quarter’s figure of 12 cents. The quarter’s adjustments exclude certain acquisition-amortization … Read more
Fulgent Genetics, Inc. (FLGT Quick QuoteFLGT – Free Report) came out with quarterly earnings of $0.78 per share, beating the Zacks Consensus Estimate of $0.73 per share. This compares to earnings of $2.55 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 6.85%. A … Read more
The long history of financial markets, like most classic novels, is full of misunderstandings, miscalculations and mistakes. Despite all of this, the story normally twists and turns its way to a happy ending. This may yet be the case for investors in the very unusual economy that has unfolded following the pandemic recession and recovery. … Read more
Seattle Genetics (SGEN Quick QuoteSGEN – Free Report) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to a loss of $0.47 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of … Read more